Siproudhis L, Sébille V, Pigot F, Hémery P, Juguet F, Bellissant E
Service des Maladies de l'Appareil Digestif, Hôpital de Pontchaillou, Rennes, France.
Aliment Pharmacol Ther. 2003 Sep 1;18(5):515-24. doi: 10.1046/j.1365-2036.2003.01467.x.
Hypertonicity of internal anal sphincter plays a major role in the persistence of chronic anal fissure. Botulinum toxin could induce internal anal sphincter relaxation without the adverse effects of surgery (long-term faecal incontinence) or topical nitrates (anal burning, headaches, hypotension).
We conducted a placebo-controlled, randomised, double-blind study to assess the efficacy of a single injection of botulinum toxin in the internal anal sphincter of patients with chronic anal fissure in six ambulatory care clinics. Eligibility criteria included a mean value of post-defecation anal pain >or= 30 mm on a 100 mm visual analogue scale over the week preceding inclusion. Main endpoint was the proportion of patients with symptomatic improvement during the fourth week after inclusion (post-defecation anal pain below 10 mm).
Forty-four patients (22 in each group) were included. At inclusion, there was no significant difference between groups on age, sex ratio, pain duration, post-defecation anal pain, analgesic consumption and stool frequency. Ten (45%) and 11 (50%) patients reported symptomatic improvement on the main endpoint (P=0.76) in placebo and botulinum toxin groups, respectively. Ten patients (five in each group) had healed fissure at week 4 and ten patients (five in each group) required surgical treatment between weeks 4 and 12. Similarly, there was no significant difference between groups on other variables between weeks 4 and 12.
The efficacy of a single injection of botulinum toxin in the internal anal sphincter does not differ from that of a placebo in patients with chronic anal fissure.
肛门内括约肌高张力在慢性肛裂的持续存在中起主要作用。肉毒杆菌毒素可诱导肛门内括约肌松弛,且无手术(长期大便失禁)或局部使用硝酸盐(肛门灼痛、头痛、低血压)的不良反应。
我们在六家门诊诊所进行了一项安慰剂对照、随机、双盲研究,以评估单次注射肉毒杆菌毒素对慢性肛裂患者肛门内括约肌的疗效。纳入标准包括在纳入前一周,排便后肛门疼痛在100mm视觉模拟量表上的平均值≥30mm。主要终点是纳入后第四周症状改善的患者比例(排便后肛门疼痛低于10mm)。
纳入44例患者(每组22例)。纳入时,两组在年龄、性别比例、疼痛持续时间、排便后肛门疼痛、镇痛药使用情况和大便频率方面无显著差异。安慰剂组和肉毒杆菌毒素组分别有10例(45%)和11例(50%)患者在主要终点报告症状改善(P=0.76)。10例患者(每组5例)在第4周肛裂愈合,10例患者(每组5例)在第4周至12周需要手术治疗。同样,在第4周和第12周之间,两组在其他变量上也无显著差异。
对于慢性肛裂患者,单次注射肉毒杆菌毒素至肛门内括约肌的疗效与安慰剂无异。